[1] |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
|
[2] |
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma[J].J Hepatol, 2018, 69(1):182-236.
|
[3] |
Tsilimigras DI, Bagante F, Sahara K, et al. Prognosis after resection of Barcelona clinic liver cancer (BCLC) stage 0, A, and B hepatocellular carcinoma: a comprehensive assessment of the current BCLC classification[J]. Ann Surg Oncol, 2019, 26(11):3693-3700.
|
[4] |
中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 中华消化外科杂志, 2020, 19(1):1-20.
|
[5] |
Yau T, Tang VY, Yao TJ, et al. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma[J]. Gastroenterology, 2014, 146(7):1691-1700, e3.
|
[6] |
Durand F, Valla D. Assessment of prognosis of cirrhosis[J]. Semin Liver Dis, 2008, 28(1):110-122.
|
[7] |
Christensen E. Prognostic models including the Child-Pugh, MELD and Mayo risk scores--where are we and where should we go?[J].J Hepatol, 2004, 41(2):344-350.
|
[8] |
Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade[J]. J Clin Oncol, 2015, 33(6):550-558.
|
[9] |
Zhang ZQ, Xiong L, Zhou JJ, et al. Ability of the ALBI grade to predict posthepatectomy liver failure and long-term survival after liver resection for different BCLC stages of HCC[J]. World J Surg Oncol, 2018, 16(1):208.
|
[10] |
Oh IS, Sinn DH, Kang TW, et al. Liver function assessment using albumin-bilirubin grade for patients with very early-stage hepatocellular carcinoma treated with radiofrequency ablation[J]. Dig Dis Sci, 2017, 62(11):3235-3242.
|
[11] |
Ho CHM, Chiang CL, Lee FAS, et al. Comparison of platelet-albumin-bilirubin (PALBI), albumin-bilirubin (ALBI), and Child-Pugh (CP) score for predicting of survival in advanced HCC patients receiving radiotherapy (RT)[J]. Oncotarget, 2018, 9(48):28818-28829.
|
[12] |
Tada T, Kumada T, Toyoda H, et al. Impact of albumin-bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: an analysis using time-dependent receiver operating characteristic[J]. J Gastroenterol Hepatol, 2019, 34(6):1066-1073.
|
[13] |
Li MX, Zhao H, Bi XY, et al. Prognostic value of the albumin-bilirubin grade in patients with hepatocellular carcinoma: validation in a Chinese cohort[J]. Hepatol Res, 2017, 47(8):731-741.
|
[14] |
Piscaglia F, Terzi E, Cucchetti A, et al. Treatment of hepatocellular carcinoma in Child-Pugh B patients[J]. Dig Liver Dis, 2013, 45(10):852-858.
|
[15] |
Edeline J, Blanc JF, Johnson P, et al. A multicentre comparison between Child Pugh and albumin-bilirubin scores in patients treated with sorafenib for hepatocellular carcinoma[J]. Liver Int, 2016, 36(12):1821-1828.
|
[16] |
Elshaarawy O, Alkhatib A, Elhelbawy M, et al. Validation of modified albumin-bilirubin-TNM score as a prognostic model to evaluate patients with hepatocellular carcinoma[J]. World J Hepatol, 2019, 11(6):542-552.
|
[17] |
Zhang CH, Ni XC, Chen BY, et al. Combined preoperative albumin-bilirubin (ALBI) and serum γ-glutamyl transpeptidase (GGT) predicts the outcome of hepatocellular carcinoma patients following hepatic resection[J]. J Cancer, 2019, 10(20):4836-4845.
|
[18] |
Ni JY, Fang ZT, An C, et al. Comparison of albumin-bilirubin grade, platelet-albumin-bilirubin grade and Child-Turcotte-Pugh class for prediction of survival in patients with large hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation[J]. Int J Hyperthermia, 2019, 36(1):841-853.
|
[19] |
Liao R, Li DW, Du CY, et al. Combined preoperative ALBI and FIB-4 is associated with recurrence of hepatocellular carcinoma after curative hepatectomy[J]. J Gastrointest Surg, 2018, 22(10):1679-1687.
|
[20] |
Suresh K, Owen D, Bazzi L, et al. Using indocyanine green extraction to predict liver function after stereotactic body radiation therapy for hepatocellular carcinoma[J]. Int J Radiat Oncol Biol Phys, 2018, 100(1):131-137.
|